Related Experiment Videos
Localized and systemic scleroderma show different histological responses to methotrexate therapy
M M Seyger1, F H van den Hoogen, I M van Vlijmen-Willems
1Department of Dermatology, University Hospital Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. M.Seijger@derma.azn.nl
The Journal of Pathology
|March 29, 2001
Summary
Methotrexate (MTX) treatment shows distinct histological responses in morphoea (localized scleroderma) versus systemic sclerosis. Morphoea lesions exhibit reduced tenascin and mast cells, unlike systemic sclerosis, indicating differing disease mechanisms.
Area of Science:
- Dermatology
- Immunohistochemistry
- Scleroderma Research
Background:
- Morphoea and systemic sclerosis share histological similarities and clinical response to methotrexate (MTX).
- Understanding differential treatment responses can elucidate underlying disease mechanisms.
- Investigating immunohistochemical changes provides insight into therapeutic effects.
Purpose of the Study:
- To compare the histological effects of low-dose methotrexate (MTX) treatment on morphoea and systemic sclerosis skin lesions.
- To determine if MTX induces different immunohistochemical response patterns in these distinct scleroderma subtypes.
- To evaluate changes in tenascin, mast cells, epidermal proliferation, and proteoglycans.
Main Methods:
- Skin biopsies were collected from seven morphoea and eight systemic sclerosis patients before and after 24 weeks of low-dose MTX therapy.
- Immunohistochemical staining was performed to assess tenascin, mast cell counts, epidermal proliferation, and heparan sulphate proteoglycans.
- Quantitative analysis compared pre- and post-treatment biopsies for each disease group.
Main Results:
- Morphoea lesions showed a significant reduction in tenascin staining and mast cell numbers in the active margin after MTX treatment.
- Systemic sclerosis lesions did not exhibit significant changes in tenascin staining or mast cell counts.
- No significant changes in epidermal proliferation or heparan sulphate proteoglycans were observed in either disease group.
Conclusions:
- Despite clinical similarities and response to MTX, morphoea and systemic sclerosis display distinct immunohistochemical responses to treatment.
- The differential changes in tenascin and mast cells suggest fundamental differences in the pathogenesis of morphoea versus systemic sclerosis.
- These findings challenge the notion that the skin lesions in localized and systemic sclerosis are identical, highlighting unique disease pathways.